Teva's Slow Recovery Proceeds With Flat Revenue Forecast In 2021
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.